Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug. The drug – which is in the same class as Sanofi's ...
The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by rejecting AstraZeneca’s PT010, a close competitor. AZ has confirmed that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results